The man in the center is more depressed than Alkermes' investors are today. Image source: Getty Images.Alkermes (NASDAQ: ALKS) is up 30% at 12:43 p.m. EDT after announcing positive phase 3 trial data for its antidepressant drug ALKS 5461.Continue reading